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Antibodies are a key part of the
body’s arsenal to fight disease. The
immune system’s unique ability to
create a specific antibody for any out
of billions of different molecular
motifs (potential antigens) protects
us quite efficiently against invaders
of all sorts. Outside the confines of
the body, however, applications of
antibodies have primarily focused on
high sensitivity detection of their
antigens. Well-known examples
include the specific protein detection
in the western blot, ELISA, and the
blue-stripe home pregnancy assay
kits. 
But over the last few years,
academic researchers and a few
biotech start-up companies have
developed new ways of using
antibodies for the job they are
supposed to do, fighting disease. The
molecules range from full size
immunoglobulins to miniaturized
binders (minibodies), the sources
from human to llama, the targets
from arthritis to psoriasis. 
Starting with ordinary human
antibodies – what if the immune
system doesn’t produce the one you
need? Can you get it off the shelf?
This is the problem that the
company MorphoSys has addressed
in Martinsried near Munich.
Founded in 1992 by the New
Zealander Simon Moroney,
MorphoSys has developed a system
that can produce any or all of the
around ten billion different human
antibodies, which they call HuCAL
(Human Combinatorial Antibody
Library). Thus, if someone comes up
with a new vaccine (that should be
recognized by an antibody) or
another drug (that shouldn’t), they
can easily test it with this antibody
library, before they take the big step
into clinical trials. It will also be
straightforward to screen this library
for human antibodies that might be
suitable for therapeutic applications
themselves. 
It looks as though monoclonals
are ready to move back to the
body
Another company specializing on
entirely human antibodies for
applications in therapy is the
California-based Abgenix. Their
most advanced product is an
antibody against the receptor of the
epidermal growth factor, called ABX-
EGF. Many tumours rely on this
growth factor and overexpress its
receptor. Preclinical research
suggests that this antibody could
block tumour growth and even
eradicate established tumours. In
collaboration with one of the oldest
biotech companies, Immunex,
Abgenix are currently putting ABX-
EGF through clinical Phase 2 trials
for kidney cancers. Trials for other
tumours are also in the pipeline. 
Beyond the human immune
systems, there may be different
kinds of antibodies, which can even
be more efficient in fighting certain
diseases. One of the most promising
research lines emerged from a chance
discovery in a Belgian teaching lab,
back in the late 1980s. Students
found that a major fraction of the
immune serum of dromedaries (as
well as other camelidae including
camels and llamas) consisted of
antibodies devoid of light chains.
This implies that each of the two
binding regions (at the upper tips of
the ‘Y’-shape) consists of only one
protein chain. Which in turn means
that most of the bulky rest of the
antibody can be cut off, leaving a
single domain (SD) antibody with
full binding specificity. 
Research carried out by the
groups of Serge Muyldermans and
Lode Wyns at the Brussels Free
University shows that these camel-
style SD antibodies can be easily
expressed in bacteria and produced
in mass quantities. Their improved
userfriendliness in comparison with
full-sized human antibodies makes
them ideally suited for biotech
applications, and several companies
including Unilever are developing
products based on their unique
properties. 
Together with Katja Els Conrath
at the same university, Wyns and
Muyldermans have also shown that
SD antibodies of one specificity can
be genetically linked with a second
type to form compact bi-specific
constructs. Similarly, they could be
linked with an enzyme. Such
constructs could be used to bring cell
types together – for instance to get
macrophages to kill off cancer cells. 
Similar ideas have inspired the
founders of Trion Pharma, a spin-off
company based on research
conducted by the group of Horst
Lindhofer at the GSF institute and
the Ludwig-Maximilians-University
Munich (www.trionpharma.com). To
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improve the inefficient immune
response to cancer cells, they
developed bispecific antibodies (each
arm of the ‘Y’ recognizing a different
antigen) designed to bring cancer
antigens in close proximity to T cells
or other elements of the immune
system required for an efficient
response. In 1997, they could
demonstrate that this approach
conveyed a lasting immunity to
melanoma and B-cell lymphoma. 
Since the foundation of Trion
Pharma in 1998, Lindhofer and his
co-workers have focused on
trifunctional antibodies, in which not
only the two arms of the ‘Y’ recognise
different antigens, but the ‘foot’ has a
third binding specificity. Such a
construct could bring together a
tumour cell, a T cell and an accessory
cell. This arrangement is crucial both
for the survival of the T cell and for
the efficient destruction of the
tumour cell. It also ensures that
tumour antigens get properly
displayed so the immune system can
step up the battle against other cells
originating from the same tumour. 
One product containing such
antibodies is already on sale
throughout Europe. Removall(R) is
applied in conjunction with
chemotherapy in advanced breast
cancer, where it is used to purify
ex vivo stem cell preparations of any
tumour cells before they are
reimplanted. Clinical studies on
in vivo applications of the drug are
scheduled to begin later this year. 
More than a quarter-century has
passed since antibodies were
domesticated by the invention of
hybridoma cultures that produce
monoclonal antibodies (i.e. with a
single specificity). After decades
spent doing interesting things in the
lab, now it looks as though
monoclonals are ready to move back
to the body and step up the fight
against disease. 
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